ADR Biomedical Holdings (TSE:3750) FCF Margin %: -1,308.50% (As of Mar. 2026)

What is ADR Biomedical Holdings FCF Margin %?

ADR Biomedical Holdings TSE:3750 -1.23% 30 FCF Margin % is -1,308.50% as of Mar. 2026. GuruFocus rates TSE:3750 with a GF Score™ of 30/100 and a GF Value™ of 円40.42 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 948 Biotechnology companies, ADR Biomedical Holdings ranks worse than 83.02% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ADR Biomedical Holdings's Free Cash Flow for the six months ended in Mar. 2026 was 円-427.99 Mil. ADR Biomedical Holdings's Revenue for the six months ended in Mar. 2026 was 円32.71 Mil. Therefore, ADR Biomedical Holdings's FCF Margin % for the quarter that ended in Mar. 2026 was -1,308.50%.

As of today, ADR Biomedical Holdings's current FCF Yield % is -10.92%.

The historical rank and industry rank for ADR Biomedical Holdings's FCF Margin % or its related term are showing as below:

TSE:3750' s FCF Margin % Range Over the Past 10 Years
Min: -1539.13 Med: -18.39 Max: 65.4
Current: -1539.13

During the past 13 years, the highest FCF Margin % of ADR Biomedical Holdings was 65.40%. The lowest was -1539.13%. And the median was -18.39%.

TSE:3750's FCF Margin % is ranked worse than
83.02% of 948 companies
in the Biotechnology industry
Industry Median: -81.28 vs TSE:3750: -1539.13

ADR Biomedical Holdings FCF Margin % Related Terms

ADR Biomedical Holdings FCF Margin % Historical Data

* Premium members only.

The historical data trend for ADR Biomedical Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADR Biomedical Holdings FCF Margin % Chart

ADR Biomedical Holdings Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

FCF Margin %

Get a 7-Day Free Trial

-27.54

-9.23

-74.88

-814.31

-1,539.13

ADR Biomedical Holdings Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25	Mar26
FCF Margin %	Get a 7-Day Free Trial															-114.34	-468.52	-1,841.79	-1,951.79	-1,308.50

TSE:3750 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, ADR Biomedical Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ADR Biomedical Holdings FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ADR Biomedical Holdings's FCF Margin % falls into.

Save Embed

30GF Score

ADR Biomedical Holdings Inc TSE:3750

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

ADR Biomedical Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ADR Biomedical Holdings's FCF Margin for the fiscal year that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2026 )	/	Revenue (A: Mar. 2026 )
	=	-784.773	/	50.988
	=	-1,539.13 %

ADR Biomedical Holdings's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-427.985	/	32.708
	=	-1,308.50 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of -1,308.50% mean?

ADR Biomedical Holdings (TSE:3750) has a FCF Margin % of -1,308.50% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ADR Biomedical Holdings and its competitors. According to the industry distribution chart, ADR Biomedical Holdings ranks #787 out of 948 companies in the Biotechnology industry, placing it in the top 83%.

Is ADR Biomedical Holdings' FCF Margin % too high?

ADR Biomedical Holdings' current FCF Margin % is -1,308.50%. Based on the distribution chart, ADR Biomedical Holdings ranks #787 out of 948 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ADR Biomedical Holdings has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does ADR Biomedical Holdings' FCF Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, ADR Biomedical Holdings ranks #787 out of 948 companies for FCF Margin %. This places ADR Biomedical Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ADR Biomedical Holdings and its competitors. ADR Biomedical Holdings's current FCF Margin % is -1,308.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is ADR Biomedical Holdings stock overvalued right now?

Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円40.42, compared to a current price of 円805.00 — trading 1891.6% above its estimated fair value. The current FCF Margin % is -1,308.50%. ADR Biomedical Holdings' overall GF Score™ is 30/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current FCF Margin % is -1,308.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?

Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued. The current stock price of 円805.00 is trading 1891.6% above its estimated GF Value™ of 円40.42. GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.

Key valuation signals for TSE:3750:

FCF Margin %: -1,308.50%
GF Value™: 円40.42 vs. price of 円805.00 (1891.6% above fair value)
GF Score™: 30/100 with 9 warning signs

No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADR Biomedical Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies TSE:4584 TSE:7096 TSE:2370 TSE:2385 TSE:4594 TSE:4564 TSE:4880 TSE:4572 TSE:7776 TSE:4596 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004

Website https://www.cytori.co.jp

ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.

30GF Score

Get the complete analysis for TSE:3750

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円805.00

Price

円40.42

GF Value

View TSE:3750 Analysis

See FCF Margin % data for all stocks →